<?xml version="1.0" encoding="UTF-8" standalone="yes"?><?xml-stylesheet type="text/xsl" href="/oai-pmh-repository/static/oai2.xsl"?>
<OAI-PMH xmlns="http://www.openarchives.org/OAI/2.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd">
    <responseDate>2026-10-13T04:06:48Z</responseDate>
    <request verb="GetRecord" identifier="oai:data.mendeley.com/dm5jj4s7z3.1" metadataPrefix="oai_dc">https://data.mendeley.com/oai</request>
    <GetRecord>
        <record>
            <header>
                <identifier>oai:data.mendeley.com/dm5jj4s7z3.1</identifier>
                <datestamp>2026-08-10T14:47:31Z</datestamp>
            </header>
            <metadata><oai_dc:dc xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd" xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <dc:creator>deng, huiyang</dc:creator>
    <dc:title>Acute Undifferentiated Leukemia </dc:title>
    <dc:publisher>Mendeley Data</dc:publisher>
    <dc:description>This dataset fills a critical gap in published AUL evidence: prior studies only document venetoclax–azacitidine dual therapy, while no public clinical data exists for the triple regimen (azacitidine + venetoclax + sorafenib) in patients with dual FLT3 missense mutations. All uploaded tables contain granular cycle-by-cycle drug doses, early drug discontinuation timelines and full supportive medication records (G-CSF, eltrombopag, anti-infectives), details condensed within the original manuscript.
Researchers may reuse this dataset for two core analyses:
Compare this case’s unique immunophenotype with MPAL/AML-M0 using the full flow cytometry panel;
Pool the FLT subclonal mutation data with existing cohorts to analyze outcomes of non-ITD FLT3 variants. Serial MRD records offer real-world reference for MRD-guided dose de-escalation in elderly unfit leukemia patients.
All images have been fully de-identified: hospital watermarks, specimen barcodes and sampling timestamps are cropped completely. No data can be cross-matched to inpatient archives, fully complying with institutional ethics rules and the Declaration of Helsinki. The CC-BY 4.0 license allows non-commercial academic reuse, provided users cite both the original manuscript and this dataset DOI.
Key interpretative reminders: Permanent megakaryocyte loss is a combined toxic effect of three myelosuppressive agents, not sorafenib alone. Readers must differentiate transient post-cycle cytopenia from irreversible marrow hypoplasia shown on follow-up bone marrow slides.
Restrictions apply to raw NGS fastq files and full electronic medical records per local human genetic regulations. Researchers needing unprocessed sequencing data must submit a formal request with institutional ethical certification and a non-commercial data use agreement to the corresponding author. Any attempt to trace patient identity or utilize these data for commercial research is prohibited.</dc:description>
    <dc:subject>Hematology</dc:subject>
    <dc:subject>Medical Genetics</dc:subject>
    <dc:subject>Case Report</dc:subject>
    <dc:type>Dataset</dc:type>
    <dc:identifier>doi:10.17632/dm5jj4s7z3.1</dc:identifier>
    <dc:identifier>oai:data.mendeley.com/dm5jj4s7z3.1</dc:identifier>
    <dc:rights>Creative Commons Attribution 4.0 International</dc:rights>
    <dc:rights>http://creativecommons.org/licenses/by/4.0</dc:rights>
    <dc:relation>https://data.mendeley.com/datasets/dm5jj4s7z3</dc:relation>
    <dc:date>2026-08-10T14:47:31Z</dc:date>
</oai_dc:dc></metadata>
        </record>
    </GetRecord>
</OAI-PMH>
